As of 2026-06-11, the EV/EBITDA ratio of Cytosorbents Corp (CTSO) is -3.33. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. CTSO's latest enterprise value is 37.95 mil USD. CTSO's TTM EBITDA according to its financial statements is -11.40 mil USD. Dividing these 2 quantities gives us the above CTSO EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.6x - 15.6x | 14.4x |
| Forward P/E multiples | 16.2x - 20.9x | 18.5x |
| Fair Price | (3.13) - (3.02) | (3.18) |
| Upside | -860.6% - -835.9% | -874.6% |
| Date | EV/EBITDA |
| 2026-06-05 | -3.59 |
| 2026-06-04 | -3.75 |
| 2026-06-03 | -3.76 |
| 2026-06-02 | -3.71 |
| 2026-06-01 | -3.64 |
| 2026-05-29 | -3.77 |
| 2026-05-28 | -3.80 |
| 2026-05-27 | -3.78 |
| 2026-05-26 | -3.61 |
| 2026-05-22 | -3.60 |
| 2026-05-21 | -3.60 |
| 2026-05-20 | -3.65 |
| 2026-05-19 | -3.67 |
| 2026-05-18 | -3.71 |
| 2026-05-15 | -3.81 |
| 2026-05-14 | -4.05 |
| 2026-05-13 | -4.21 |
| 2026-05-12 | -4.29 |
| 2026-05-11 | -4.54 |
| 2026-05-08 | -4.42 |
| 2026-05-07 | -4.42 |
| 2026-05-06 | -4.21 |
| 2026-05-05 | -4.40 |
| 2026-05-04 | -4.48 |
| 2026-05-01 | -4.45 |
| 2026-04-30 | -4.43 |
| 2026-04-29 | -4.57 |
| 2026-04-28 | -4.37 |
| 2026-04-27 | -4.44 |
| 2026-04-24 | -4.53 |
| 2026-04-23 | -4.64 |
| 2026-04-22 | -4.54 |
| 2026-04-21 | -4.49 |
| 2026-04-20 | -4.62 |
| 2026-04-17 | -4.70 |
| 2026-04-16 | -4.43 |
| 2026-04-15 | -4.32 |
| 2026-04-14 | -4.31 |
| 2026-04-13 | -4.29 |
| 2026-04-10 | -4.43 |
| 2026-04-09 | -4.40 |
| 2026-04-08 | -4.48 |
| 2026-04-07 | -4.43 |
| 2026-04-06 | -4.32 |
| 2026-04-02 | -4.28 |
| 2026-04-01 | -4.08 |
| 2026-03-31 | -4.18 |
| 2026-03-30 | -4.15 |
| 2026-03-27 | -4.33 |
| 2026-03-26 | -4.37 |